Ozurdex is a biodegradable dexamethasone implant placed into the vitreous cavity in cases that are predisposed to development of macular edema due to retinal vein occlusion, noninfectious uveitis or diabetes.
The implant, from AbbVie, gradually releases 0.7 mg dexamethasone into the intravitreal cavity and eventually degrades into glycolic and lactic acid. The desired placement of the implant is into the intravitreal cavity; however, cases have been reported in which anterior migration of the implant is seen, eventually leading to the development of significant complications and undesired